Key result
The monoclonal antibody 5G3 potently neutralizes echovirus 3 (Neut50 0.34 nM) by binding to a serotype-specific epitope and sterically blocking interactions with viral receptors CD55 and FcRn.
Why the study?
Echovirus 3 causes severe diseases such as aseptic meningitis, myocarditis, and anicteric hepatitis, but there are no approved vaccines or antiviral drugs for HEV-B group infections.
Effect estimate: Neut50 0.34 nM
The study provides the structural basis for the neutralization of echovirus 3 by the 5G3 antibody, offering insights for rational drug and vaccine design against HEV-B infections.
May guide E3 antibody therapies; leaves open clinical translation pending trials.
Human enteroviruses (HEVs) are ubiquitous pathogens responsible for multiple human diseases, ranging from hand-foot-and-mouth disease (HFMD), meningitis, to poliomyelitis, encephalitis, etc 1 . HEVs comprise four main groups, Enterovirus A–D (HEV-A, B, C, and D), among which HEV-B is the largest group, including coxsackievirus A9 (CVA9), coxsackievirus B1–6 (CVB1–6), and over 30 serotypes of echoviruses. Echovirus 3 (E3), a serotype of HEV-B, first isolated in 1953, leads to highly contagious and severe diseases in humans, such as aseptic meningitis, myocarditis, and anicteric hepatitis 2 . Infection in neonates and infants within the first few weeks of life can be fatal. Currently, there are no approved vaccines or antiviral drugs for treating infections caused by viruses belonging to the HEV-B group.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2021) conducted a letter in Echovirus 3 (E3) infection. 5G3 monoclonal antibody was evaluated on Neutralization of E3 by 5G3 (Neut50 0.34 nM). The monoclonal antibody 5G3 potently neutralizes echovirus 3 (Neut50 0.34 nM) by binding to a serotype-specific epitope and sterically blocking interactions with viral receptors CD55 and FcRn.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: